- Home
- AOD vs IMTX Comparison
AOD vs IMTX Comparison
Compare AOD & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOD
- IMTX
- Stock Information
- Founded
- AOD 2006
- IMTX N/A
- Country
- AOD United Kingdom
- IMTX Germany
- Employees
- AOD N/A
- IMTX N/A
- Industry
- AOD Investment Managers
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AOD Finance
- IMTX Health Care
- Exchange
- AOD Nasdaq
- IMTX Nasdaq
- Market Cap
- AOD 1.0B
- IMTX 1.1B
- IPO Year
- AOD N/A
- IMTX N/A
- Fundamental
- Price
- AOD $9.20
- IMTX $9.04
- Analyst Decision
- AOD
- IMTX Strong Buy
- Analyst Count
- AOD 0
- IMTX 4
- Target Price
- AOD N/A
- IMTX $13.67
- AVG Volume (30 Days)
- AOD 423.5K
- IMTX 679.4K
- Earning Date
- AOD 01-01-0001
- IMTX 11-14-2025
- Dividend Yield
- AOD 12.95%
- IMTX N/A
- EPS Growth
- AOD 213.63
- IMTX N/A
- EPS
- AOD 1.93
- IMTX N/A
- Revenue
- AOD $72,962,082.00
- IMTX $152,823,253.00
- Revenue This Year
- AOD N/A
- IMTX N/A
- Revenue Next Year
- AOD N/A
- IMTX $13.52
- P/E Ratio
- AOD $4.44
- IMTX N/A
- Revenue Growth
- AOD N/A
- IMTX 83.61
- 52 Week Low
- AOD $6.99
- IMTX $3.30
- 52 Week High
- AOD $9.14
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- AOD 31.97
- IMTX 44.41
- Support Level
- AOD $9.49
- IMTX $9.99
- Resistance Level
- AOD $9.66
- IMTX $10.70
- Average True Range (ATR)
- AOD 0.12
- IMTX 0.50
- MACD
- AOD -0.05
- IMTX -0.29
- Stochastic Oscillator
- AOD 10.55
- IMTX 13.89
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.